Free Trial

HRMY FY2025 EPS Estimate Reduced by Cantor Fitzgerald

Harmony Biosciences logo with Medical background

Key Points

  • Cantor Fitzgerald has reduced its FY2025 EPS estimate for Harmony Biosciences from $2.68 to $2.19, while maintaining a "Strong-Buy" rating on the stock.
  • The consensus estimate for Harmony Biosciences' full-year earnings is currently $2.43 per share, indicating a potential discrepancy with Cantor Fitzgerald's revised prediction.
  • Despite the EPS downgrade, Harmony Biosciences has received multiple "buy" ratings from various analysts, with an average target price of $51.00 per share.
  • Looking to Export and Analyze Harmony Biosciences Data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Investment analysts at Cantor Fitzgerald dropped their FY2025 EPS estimates for Harmony Biosciences in a research note issued to investors on Wednesday, August 6th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings of $2.19 per share for the year, down from their previous estimate of $2.68. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Harmony Biosciences' current full-year earnings is $2.43 per share. Cantor Fitzgerald also issued estimates for Harmony Biosciences' FY2026 earnings at $1.94 EPS.

HRMY has been the topic of several other reports. Needham & Company LLC reissued a "buy" rating and set a $49.00 target price on shares of Harmony Biosciences in a research note on Tuesday, May 6th. Truist Financial began coverage on shares of Harmony Biosciences in a report on Monday, July 21st. They issued a "buy" rating and a $48.00 price target for the company. Oppenheimer began coverage on shares of Harmony Biosciences in a research note on Monday, June 2nd. They set an "outperform" rating and a $61.00 price target on the stock. Mizuho raised their price objective on shares of Harmony Biosciences from $44.00 to $48.00 and gave the stock an "outperform" rating in a report on Thursday, May 15th. Finally, UBS Group lowered their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Monday, April 28th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Harmony Biosciences presently has an average rating of "Buy" and a consensus target price of $51.00.

View Our Latest Stock Report on HRMY

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY opened at $34.45 on Friday. Harmony Biosciences has a one year low of $26.47 and a one year high of $41.61. The company has a market capitalization of $1.98 billion, a PE ratio of 11.11, a price-to-earnings-growth ratio of 0.51 and a beta of 0.84. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.63 and a current ratio of 3.84. The stock has a fifty day moving average of $34.17 and a 200-day moving average of $33.88.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.78 by ($0.10). The business had revenue of $200.49 million during the quarter, compared to the consensus estimate of $204.37 million. Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%. The company's revenue for the quarter was up 16.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.05 EPS.

Hedge Funds Weigh In On Harmony Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC increased its holdings in Harmony Biosciences by 1.9% in the fourth quarter. FMR LLC now owns 5,329,902 shares of the company's stock valued at $183,402,000 after purchasing an additional 101,182 shares during the last quarter. Deep Track Capital LP bought a new stake in Harmony Biosciences in the fourth quarter valued at approximately $49,894,000. American Century Companies Inc. boosted its position in shares of Harmony Biosciences by 16.9% during the first quarter. American Century Companies Inc. now owns 1,288,787 shares of the company's stock worth $42,775,000 after purchasing an additional 186,183 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Harmony Biosciences by 15.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,213,029 shares of the company's stock valued at $41,739,000 after buying an additional 160,490 shares during the period. Finally, LSV Asset Management raised its position in shares of Harmony Biosciences by 25.0% during the first quarter. LSV Asset Management now owns 1,194,961 shares of the company's stock worth $39,661,000 after purchasing an additional 238,744 shares during the period. 86.23% of the stock is owned by institutional investors.

Harmony Biosciences Company Profile

(Get Free Report)

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Further Reading

Earnings History and Estimates for Harmony Biosciences (NASDAQ:HRMY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Harmony Biosciences Right Now?

Before you consider Harmony Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.

While Harmony Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines